Odalasvir
Odalasvir is an investigational new drug in development for the treatment of hepatitis C. It is an Discovery and development of [NS5A inhibitors|NS5A inhibitor]. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by Achillion Pharmaceuticals.